Markets:

Overview

News

Currencies

International

Treasuries

IVERIC bio, Inc. - Common Stock (NQ:ISEE)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 10, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about IVERIC bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >

IVERIC bio Inc. (NASDAQ: ISEE) Records 52-Week High Thursday Morning

July 06, 2023

Via Investor Brand Network

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 05, 2023

From IVERIC bio, Inc.

Via Business Wire

IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE

June 14, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

IVERIC bio Inc. (NASDAQ: ISEE) Making Surprising Moves in Monday Session

June 05, 2023

Via Investor Brand Network

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2023

From IVERIC bio, Inc.

Via Business Wire

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

June 01, 2023

By David Willey, Benzinga

Via TheNewswire.com

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 24, 2023

From IVERIC bio, Inc.

Via Business Wire

IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE

May 02, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Iveric Bio Inc. (Nasdaq – ISEE), Midwest Holding Inc. (Nasdaq – MDWT), Hoth Therapeutics, Inc. (Nasdaq – HOTH)

May 01, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

ISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to Shareholders

May 01, 2023

From Halper Sadeh LLC

Via Business Wire

Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

April 30, 2023

From IVERIC Bio, Inc.

Via Business Wire

Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting

April 23, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 02, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results

March 01, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials

March 01, 2023

From Iveric Bio

Via Business Wire

Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference

February 28, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023

February 22, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy

February 16, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 04, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors

January 03, 2023

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

December 20, 2022

From Iveric bio, Inc.

Via Business Wire

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 02, 2022

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock

November 30, 2022

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Announces Proposed Offering of Common Stock

November 30, 2022

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

November 17, 2022

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio to Present at Upcoming Investor Conferences

November 04, 2022

From Iveric Bio

Via Business Wire

Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

November 03, 2022

From IVERIC bio, Inc.

Via Business Wire

Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

November 03, 2022

From IVERIC bio, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.